[Effect of glatiramer acetate (copaxone) on the structure and functions of the thyroid gland in patients with multiple sclerosis]
Related Experiment Video
Updated: Jun 4, 2026

Positron Emission Tomography Imaging for In Vivo Measuring of Myelin Content in the Lysolecithin Rat Model of Multiple Sclerosis
Published on: February 28, 2021
Abstract:
A study included 158 patients stratified into 3 groups: 57 patients with multiple sclerosis (MS) of the main group who were treated with copaxone in dosage 20 mg/d during 4,3±2,6 years, 49 patients without MS with different neurological diseases of the control group and 52 patients diagnosed with "confirmed MS" in the remission stage who were not treated with disease-modifying drugs. Demographic data, severity of MS patient's state, ultra-sound and hormonal data assessing the thyroid gland function were analyzed. The results obtained in the study demonstrated the relative safety of copaxone in respect to changes in thyroid gland function, the low risk for the elevation of blood antibodies to thyreoperoxidase, changes of hormonal indices and the development of thyroid dysfunction.
Related Concept Videos
Graves Disease II: Pathophysiology
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Graves' Disease I: Introduction
Hypothyroidism II: Pathophysiology
Hyperthyroidism II: Pathophysiology
Multiple Sclerosis l: Introduction
